Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma

In spite of high-dose chemotherapy followed by autologous hematopoietic SCT multiple myeloma (MM) eventually recurs, highlighting the need for more effective treatment approaches. Patients received topotecan 3.5 mg/m(2) intravenously on days −6 to −2, melphalan 70 mg/m(2) intravenously on days −3 an...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kazmi, SMA, Saliba, RM, Donato, M, Wang, M, Hosing, C, Qureshi, S, Anderlini, P, Popat, U, Champlin, RE, Giralt, SA, Qazilbash, MH
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4080410/
https://ncbi.nlm.nih.gov/pubmed/20581887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2010.160
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares